

Please add the following new claims:

--69. A recombinant polypeptide which is nonglycosylated or has a glycosylation pattern different from urinary-derived TNF inhibitor and has the ability to bind to TNF, wherein said polypeptide is encoded by DNA selected from the group consisting of:

A) DNA comprising the sequence:

*Handwritten: 2*

R <sup>2</sup>	GAT	AGT	GTG	TGT	CCC	CAA	GGA	AAA	TAT	ATC	CAC	CCT	CAA
AAT	AAT	TCG	ATT	TGC	TGT	ACC	AAG	TGC	CAC	AAA	GGA	ACC	TAC
TTG	TAC	AAT	GAC	TGT	CCA	GGC	CCG	GGG	CAG	GAT	ACG	GAC	TGC
AGG	GAG	TGT	GAG	AGC	GGC	TCC	TTC	ACC	GCT	TCA	GAA	AAC	CAC
CTC	AGA	CAC	TGC	CTC	AGC	TGC	TCC	AAA	TGC	CGA	AAG	GAA	ATG
GGT	CAG	GTG	GAG	ATC	TCT	TCT	TGC	ACA	GTG	GAC	CGG	GAC	ACC
GTG	TGT	GGC	TGC	AGG	AAG	AAC	CAG	TAC	CGG	CAT	TAT	TGG	AGT
GAA	AAC	CTT	TTC	CAG	TGC	TTC	AAT	TGC	AGC	CTC	TGC	CTC	AAT
GGG	ACC	GTG	CAC	CTC	TCC	TGC	CAG	GAG	AAA	CAG	AAC	ACC	GTG
TGC	ACC	TGC	CAT	GCA	GGT	TTC	TTT	CTA	AGA	GAA	AAC	GAG	TGT
GTC	TCC	TGT	AGT	AAC	TGT	AAG	AAA	AGC	CTG	GAG	TGC	ACG	AAG
TTG	TGC	CTA	CCC	CAG	ATT	GAG	AAT						

*Handwritten: 3*  
 , or a C- and/or N- terminally shortened sequence thereof, wherein R<sup>2</sup> is absent or is a DNA comprising a sequence coding for a polypeptide which can be cleaved *in vivo*; and

B) DNA comprising the sequence:

*Handwritten: 3*

R <sup>2</sup>	GAT	AGT	GTG	TGT	CCC	CAA	GGA	AAA	TAT	ATC	CAC	CCT	CAA
AAT	AAT	TCG	ATT	TGC	TGT	ACC	AAG	TGC	CAC	AAA	GGA	ACC	TAC
TTG	TAC	AAT	GAC	TGT	CCA	GGC	CCG	GGG	CAG	GAT	ACG	GAC	TGC
AGG	GAG	TGT	GAG	AGC	GGC	TCC	TTC	ACC	GCT	TCA	GAA	AAC	CAC
CTC	AGA	CAC	TGC	CTC	AGC	TGC	TCC	AAA	TGC	CGA	AAG	GAA	ATG
GGT	CAG	GTG	GAG	ATC	TCT	TCT	TGC	ACA	GTG	GAC	CGG	GAC	ACC
GTG	TGT	GGC	TGC	AGG	AAG	AAC	CAG	TAC	CGG	CAT	TAT	TGG	AGT
GAA	AAC	CTT	TTC	CAG	TGC	TTC	AAT	TGC	AGC	CTC	TGC	CTC	AAT
GGG	ACC	GTG	CAC	CTC	TCC	TGC	CAG	GAG	AAA	CAG	AAC	ACC	GTG
TGC	ACC	TGC	CAT	GCA	GGT	TTC	TTT	CTA	AGA	GAA	AAC	GAG	TGT
GTC	TCC	TGT	AGT	AAC	TGT	AAG	AAA	AGC	CTG	GAG	TGC	ACG	AAG
TTG	TGC	CTA	CCC	CAG	ATT	GAG	AAT	GTT	AAG	GGC	ACT	GAG	GAC
TCA	GGC	ACC	ACA										

, or a C- and/or N- terminally shortened sequence thereof, wherein R<sup>2</sup> is absent or represents DNA coding for a polypeptide which can be cleaved *in vivo*.

2  
70. Polypeptide according to claim 69, wherein R<sup>2</sup> is a DNA comprising a sequence which codes for a polypeptide which can be cleaved *in vivo*.

3  
71. Polypeptide according to claim 69, wherein R<sup>2</sup> is a DNA comprising the sequence: CTG GTC CCT CAC CTA GGG GAC AGG GAG AAG AGA, or a C- and/or N- terminally shortened sequence thereof.

4  
72. Polypeptide according to claim 69, wherein R<sup>2</sup> is a DNA encoding an amino acid sequence comprising: leu val pro his leu gly asp arg glu lys arg, or a C- and/or N- terminally shortened sequence thereof.

5  
73. Polypeptide according to claim 70, wherein R<sup>2</sup> is a DNA comprising the sequence: R<sup>3</sup> CTG GTC CCT CAC CTA GGG GAC AGG GAG AAG AGA, or a C- and/or N- terminally shortened sequence thereof, wherein R<sup>3</sup> is a DNA coding for a signal peptide.

E' cont.  
74. Polypeptide according to claim 70, wherein R<sup>2</sup> is a DNA encoding an amino acid sequence comprising: R<sup>3</sup> leu val pro his leu gly asp arg glu lys arg, or a C- and/or N- terminally shortened sequence thereof, wherein R<sup>3</sup> is a DNA coding for a signal peptide.

75. Polypeptide according to claim 73, wherein R<sup>3</sup> is a DNA comprising the sequence:

ATG GGC CTC TCC ACC GTG CCT GAC CTG CTG CTG CCA CTG GTG  
CTC CTG GAG CTG TTG GTG GGA ATA TAC CCC TCA GGG GTT ATT  
GGA

; or a C- and/or N- terminally shortened sequence thereof.

76. Polypeptide according to claim 73, wherein R<sup>3</sup> is a DNA encoding an amino acid sequence comprising:

76876  
met gly leu ser thr val pro asp leu leu leu pro leu val  
leu leu glu leu leu val gly ile tyr pro ser gly val ile  
gly

; or a C- and/or N- terminally shortened sequence thereof.

77. Polypeptide according to claim 69, wherein said polypeptide is not associated with human urinary proteins.

78. A recombinant polypeptide which is nonglycosylated or has a glycosylation pattern different from urinary-derived TNF inhibitor and has the ability to bind to TNF, wherein said polypeptide is encoded by DNA selected from the group consisting of:

A) DNA comprising the sequence:

CTG GTC CCT CAC CTA GGG GAC AGG GAG AAG AGA GAT AGT  
GTG TGT CCC CAA GGA AAA TAT ATC CAC CCT CAA AAT AAT TCG  
ATT TGC TGT ACC AAG TGC CAC AAA GGA ACC TAC TTG TAC AAT  
GAC TGT CCA GGC CCG GGG CAG GAT ACG GAC TGC AGG GAG TGT  
GAG AGC GGC TCC TTC ACC GCT TCA GAA AAC CAC CTC AGA CAC  
TGC CTC AGC TGC TCC AAA TGC CGA AAG GAA ATG GGT CAG GTG  
GAG ATC TCT TCT TGC ACA GTG GAC CGG GAC ACC GTG TGT GGC  
TGC AGG AAG AAC CAG TAC CGG CAT TAT TGG AGT GAA AAC CTT  
TTC CAG TGC TTC AAT TGC AGC CTC TGC CTC AAT GGG ACC GTG  
CAC CTC TCC TGC CAG GAG AAA CAG AAC ACC GTG TGC ACC TGC  
CAT GCA GGT TTC TTT CTA AGA GAA AAC GAG TGT GTC TCC TGT  
AGT AAC TGT AAG AAA AGC CTG GAG TGC ACG AAG TTG TGC CTA  
CCC CAG ATT GAG AAT

, or a C- and/or N- terminally shortened sequence thereof;

B) DNA comprising the sequence:

CTG GTC CCT CAC CTA GGG GAC AGG GAG AAG AGA GAT AGT  
GTG TGT CCC CAA GGA AAA TAT ATC CAC CCT CAA AAT AAT TCG  
ATT TGC TGT ACC AAG TGC CAC AAA GGA ACC TAC TTG TAC AAT  
GAC TGT CCA GGC CCG GGG CAG GAT ACG GAC TGC AGG GAG TGT  
GAG AGC GGC TCC TTC ACC GCT TCA GAA AAC CAC CTC AGA CAC  
TGC CTC AGC TGC TCC AAA TGC CGA AAG GAA ATG GGT CAG GTG  
GAG ATC TCT TCT TGC ACA GTG GAC CGG GAC ACC GTG TGT GGC  
TGC AGG AAG AAC CAG TAC CGG CAT TAT TGG AGT GAA AAC CTT  
TTC CAG TGC TTC AAT TGC AGC CTC TGC CTC AAT GGG ACC GTG  
CAC CTC TCC TGC CAG GAG AAA CAG AAC ACC GTG TGC ACC TGC  
CAT GCA GGT TTC TTT CTA AGA GAA AAC GAG TGT GTC TCC TGT  
AGT AAC TGT AAG AAA AGC CTG GAG TGC ACG AAG TTG TGC CTA  
CCC CAG ATT GAG AAT GTT AAG GGC ACT GAG GAC TCA GGC ACC  
ACA

, or a C- and/or N- terminally shortened sequence thereof;

C) DNA comprising the sequence:

```

                                     GAT AGT
GTG TGT CCC CAA GGA AAA TAT ATC CAC CCT CAA AAT AAT TCG
ATT TGC TGT ACC AAG TGC CAC AAA GGA ACC TAC TTG TAC AAT
GAC TGT CCA GGC CCG GGG CAG GAT ACG GAC TGC AGG GAG TGT
GAG AGC GGC TCC TTC ACC GCT TCA GAA AAC CAC CTC AGA CAC
TGC CTC AGC TGC TCC AAA TGC CGA AAG GAA ATG GGT CAG GTG
GAG ATC TCT TCT TGC ACA GTG GAC CGG GAC ACC GTG TGT GGC
TGC AGG AAG AAC CAG TAC CGG CAT TAT TGG AGT GAA AAC CTT
TTC CAG TGC TTC AAT TGC AGC CTC TGC CTC AAT GGG ACC GTG
CAC CTC TCC TGC CAG GAG AAA CAG AAC ACC GTG TGC ACC TGC
CAT GCA GGT TTC TTT CTA AGA GAA AAC GAG TGT GTC TCC TGT
AGT AAC TGT AAG AAA AGC CTG GAG TGC ACG AAG TTG TGC CTA
CCC CAG ATT GAG AAT
```

, or a C- and/or N- terminally shortened sequence thereof; and

D) DNA comprising the sequence:

E' cont.

```

                                     GAT AGT
GTG TGT CCC CAA GGA AAA TAT ATC CAC CCT CAA AAT AAT TCG
ATT TGC TGT ACC AAG TGC CAC AAA GGA ACC TAC TTG TAC AAT
GAC TGT CCA GGC CCG GGG CAG GAT ACG GAC TGC AGG GAG TGT
GAG AGC GGC TCC TTC ACC GCT TCA GAA AAC CAC CTC AGA CAC
TGC CTC AGC TGC TCC AAA TGC CGA AAG GAA ATG GGT CAG GTG
GAG ATC TCT TCT TGC ACA GTG GAC CGG GAC ACC GTG TGT GGC
TGC AGG AAG AAC CAG TAC CGG CAT TAT TGG AGT GAA AAC CTT
TTC CAG TGC TTC AAT TGC AGC CTC TGC CTC AAT GGG ACC GTG
CAC CTC TCC TGC CAG GAG AAA CAG AAC ACC GTG TGC ACC TGC
CAT GCA GGT TTC TTT CTA AGA GAA AAC GAG TGT GTC TCC TGT
AGT AAC TGT AAG AAA AGC CTG GAG TGC ACG AAG TTG TGC CTA
CCC CAG ATT GAG AAT GTT AAG GGC ACT GAG GAC TCA GGC ACC
ACA
```

, or a C- and/or N- terminally shortened sequence thereof.

79. Polypeptide according to claim 78, wherein said polypeptide is not associated with human urinary proteins.

80. A recombinant polypeptide which is nonglycosylated or has a glycosylation pattern different from urinary-derived TNF inhibitor and has the ability to bind to TNF, wherein said polypeptide is encoded by DNA selected from the group consisting of:

A) DNA comprising the sequence:

ATG CTG GTC CCT CAC CTA GGG GAC AGG GAG AAG AGA GAT AGT  
GTG TGT CCC CAA GGA AAA TAT ATC CAC CCT CAA AAT AAT TCG  
ATT TGC TGT ACC AAG TGC CAC AAA GGA ACC TAC TTG TAC AAT  
GAC TGT CCA GGC CCG GGG CAG GAT ACG GAC TGC AGG GAG TGT  
GAG AGC GGC TCC TTC ACC GCT TCA GAA AAC CAC CTC AGA CAC  
TGC CTC AGC TGC TCC AAA TGC CGA AAG GAA ATG GGT CAG GTG  
GAG ATC TCT TCT TGC ACA GTG GAC CGG GAC ACC GTG TGT GGC  
TGC AGG AAG AAC CAG TAC CGG CAT TAT TGG AGT GAA AAC CTT  
TTC CAG TGC TTC AAT TGC AGC CTC TGC CTC AAT GGG ACC GTG  
CAC CTC TCC TGC CAG GAG AAA CAG AAC ACC GTG TGC ACC TGC  
CAT GCA GGT TTC TTT CTA AGA GAA AAC GAG TGT GTC TCC TGT  
AGT AAC TGT AAG AAA AGC CTG GAG TGC ACG AAG TTG TGC CTA  
CCC CAG ATT GAG AAT

, or a C- and/or N- terminally shortened sequence thereof;

B) DNA comprising the sequence:

ATG CTG GTC CCT CAC CTA GGG GAC AGG GAG AAG AGA GAT AGT  
GTG TGT CCC CAA GGA AAA TAT ATC CAC CCT CAA AAT AAT TCG  
ATT TGC TGT ACC AAG TGC CAC AAA GGA ACC TAC TTG TAC AAT  
GAC TGT CCA GGC CCG GGG CAG GAT ACG GAC TGC AGG GAG TGT  
GAG AGC GGC TCC TTC ACC GCT TCA GAA AAC CAC CTC AGA CAC  
TGC CTC AGC TGC TCC AAA TGC CGA AAG GAA ATG GGT CAG GTG  
GAG ATC TCT TCT TGC ACA GTG GAC CGG GAC ACC GTG TGT GGC  
TGC AGG AAG AAC CAG TAC CGG CAT TAT TGG AGT GAA AAC CTT  
TTC CAG TGC TTC AAT TGC AGC CTC TGC CTC AAT GGG ACC GTG  
CAC CTC TCC TGC CAG GAG AAA CAG AAC ACC GTG TGC ACC TGC  
CAT GCA GGT TTC TTT CTA AGA GAA AAC GAG TGT GTC TCC TGT  
AGT AAC TGT AAG AAA AGC CTG GAG TGC ACG AAG TTG TGC CTA  
CCC CAG ATT GAG AAT GTT AAG GGC ACT GAG GAC TCA GGC ACC  
ACA

, or a C- and/or N- terminally shortened sequence thereof;

C) DNA comprising the sequence:

GTG TGT CCC CAA GGA AAA TAT ATC CAC CCT CAA AAT AAT TCG  
ATT TGC TGT ACC AAG TGC CAC AAA GGA ACC TAC TTG TAC AAT  
GAC TGT CCA GGC CCG GGG CAG GAT ACG GAC TGC AGG GAG TGT  
GAG AGC GGC TCC TTC ACC GCT TCA GAA AAC CAC CTC AGA CAC  
TGC CTC AGC TGC TCC AAA TGC CGA AAG GAA ATG GGT CAG GTG  
GAG ATC TCT TCT TGC ACA GTG GAC CGG GAC ACC GTG TGT GGC  
TGC AGG AAG AAC CAG TAC CGG CAT TAT TGG AGT GAA AAC CTT  
TTC CAG TGC TTC AAT TGC AGC CTC TGC CTC AAT GGG ACC GTG  
CAC CTC TCC TGC CAG GAG AAA CAG AAC ACC GTG TGC ACC TGC  
CAT GCA GGT TTC TTT CTA AGA GAA AAC GAG TGT GTC TCC TGT  
AGT AAC TGT AAG AAA AGC CTG GAG TGC ACG AAG TTG TGC CTA  
CCC CAG ATT GAG AAT

, or a C- and/or N- terminally shortened sequence thereof;

D) DNA comprising the sequence:

GTG TGT CCC CAA GGA AAA TAT ATC CAC CCT CAA AAT AAT TCG  
ATT TGC TGT ACC AAG TGC CAC AAA GGA ACC TAC TTG TAC AAT  
GAC TGT CCA GGC CCG GGG CAG GAT ACG GAC TGC AGG GAG TGT  
GAG AGC GGC TCC TTC ACC GCT TCA GAA AAC CAC CTC AGA CAC  
TGC CTC AGC TGC TCC AAA TGC CGA AAG GAA ATG GGT CAG GTG  
GAG ATC TCT TCT TGC ACA GTG GAC CGG GAC ACC GTG TGT GGC  
TGC AGG AAG AAC CAG TAC CGG CAT TAT TGG AGT GAA AAC CTT  
TTC CAG TGC TTC AAT TGC AGC CTC TGC CTC AAT GGG ACC GTG  
CAC CTC TCC TGC CAG GAG AAA CAG AAC ACC GTG TGC ACC TGC  
CAT GCA GGT TTC TTT CTA AGA GAA AAC GAG TGT GTC TCC TGT  
AGT AAC TGT AAG AAA AGC CTG GAG TGC ACG AAG TTG TGC CTA  
CCC CAG ATT GAG AAT GTT AAG GGC ACT GAG GAC TCA GGC ACC  
ACA

, or a C- and/or N- terminally shortened sequence thereof;

E) DNA comprising the sequence:

ATG GGC CTC TCC ACC GTG CCT GAC CTG CTG CTG CCA CTG GTG  
CTC CTG GAG CTG TTG GTG GGA ATA TAC CCC TCA GGG GTT ATT  
GGA CTG GTC CCT CAC CTA GGG GAC AGG GAG AAG AGA GAT AGT  
GTG TGT CCC CAA GGA AAA TAT ATC CAC CCT CAA AAT AAT TCG

ATT TGC TGT ACC AAG TGC CAC AAA GGA ACC TAC TTG TAC AAT  
GAC TGT CCA GGC CCG GGG CAG GAT ACG GAC TGC AGG GAG TGT  
GAG AGC GGC TCC TTC ACC GCT TCA GAA AAC CAC CTC AGA CAC  
TGC CTC AGC TGC TCC AAA TGC CGA AAG GAA ATG GGT CAG GTG  
GAG ATC TCT TCT TGC ACA GTG GAC CGG GAC ACC GTG TGT GGC  
TGC AGG AAG AAC CAG TAC CGG CAT TAT TGG AGT GAA AAC CTT  
TTC CAG TGC TTC AAT TGC AGC CTC TGC CTC AAT GGG ACC GTG  
CAC CTC TCC TGC CAG GAG AAA CAG AAC ACC GTG TGC ACC TGC  
CAT GCA GGT TTC TTT CTA AGA GAA AAC GAG TGT GTC TCC TGT  
AGT AAC TGT AAG AAA AGC CTG GAG TGC ACG AAG TTG TGC CTA  
CCC CAG ATT GAG AAT

, or a C- and/or N- terminally shortened sequence thereof;

F) DNA comprising the sequence:

ATG GGC CTC TCC ACC GTG CCT GAC CTG CTG CTG CCA CTG GTG  
CTC CTG GAG CTG TTG GTG GGA ATA TAC CCC TCA GGG GTT ATT  
GGA CTG GTC CCT CAC CTA GGG GAC AGG GAG AAG AGA GAT AGT  
GTG TGT CCC CAA GGA AAA TAT ATC CAC CCT CAA AAT AAT TCG  
ATT TGC TGT ACC AAG TGC CAC AAA GGA ACC TAC TTG TAC AAT  
GAC TGT CCA GGC CCG GGG CAG GAT ACG GAC TGC AGG GAG TGT  
GAG AGC GGC TCC TTC ACC GCT TCA GAA AAC CAC CTC AGA CAC  
TGC CTC AGC TGC TCC AAA TGC CGA AAG GAA ATG GGT CAG GTG  
GAG ATC TCT TCT TGC ACA GTG GAC CGG GAC ACC GTG TGT GGC  
TGC AGG AAG AAC CAG TAC CGG CAT TAT TGG AGT GAA AAC CTT  
TTC CAG TGC TTC AAT TGC AGC CTC TGC CTC AAT GGG ACC GTG  
CAC CTC TCC TGC CAG GAG AAA CAG AAC ACC GTG TGC ACC TGC  
CAT GCA GGT TTC TTT CTA AGA GAA AAC GAG TGT GTC TCC TGT  
AGT AAC TGT AAG AAA AGC CTG GAG TGC ACG AAG TTG TGC CTA  
CCC CAG ATT GAG AAT GTT AAG GGC ACT GAG GAC TCA GGC ACC  
ACA

, or a C- and/or N- terminally shortened sequence thereof;

G) DNA comprising the sequence:

ATG GGC CTC TCC ACC GTG CCT GAC CTG CTG CTG CCA CTG GTG  
CTC CTG GAG CTG TTG GTG GGA ATA TAC CCC TCA GGG GTT ATT  
GGA GAT AGT GTG TGT CCC CAA GGA AAA TAT ATC CAC CCT CAA

AAT AAT TCG ATT TGC TGT ACC AAG TGC CAC AAA GGA ACC TAC TTG  
TAC AAT GAC TGT CCA GGC CCG GGG CAG GAT ACG GAC TGC AGG  
GAG TGT GAG AGC GGC TCC TTC ACC GCT TCA GAA AAC CAC CTC  
AGA CAC TGC CTC AGC TGC TCC AAA TGC CGA AAG GAA ATG GGT  
CAG GTG GAG ATC TCT TCT TGC ACA GTG GAC CGG GAC ACC GTG  
TGT GGC TGC AGG AAG AAC CAG TAC CGG CAT TAT TGG AGT GAA  
AAC CTT TTC CAG TGC TTC AAT TGC AGC CTC TGC CTC AAT GGG  
ACC GTG CAC CTC TCC TGC CAG GAG AAA CAG AAC ACC GTG TGC  
ACC TGC CAT GCA GGT TTC TTT CTA AGA GAA AAC GAG TGT GTC  
TCC TGT AGT AAC TGT AAG AAA AGC CTG GAG TGC ACG AAG TTG  
TGC CTA CCC CAG ATT GAG AAT

, or a C- and/or N- terminally shortened sequence thereof;

H) DNA comprising the sequence:

ATG GGC CTC TCC ACC GTG CCT GAC CTG CTG CTG CCA CTG GTG  
CTC CTG GAG CTG TTG GTG GGA ATA TAC CCC TCA GGG GTT ATT  
GGA GAT AGT GTG TGT CCC CAA GGA AAA TAT ATC CAC CCT CAA  
AAT AAT TCG ATT TGC TGT ACC AAG TGC CAC AAA GGA ACC TAC  
TTG TAC AAT GAC TGT CCA GGC CCG GGG CAG GAT ACG GAC TGC  
AGG GAG TGT GAG AGC GGC TCC TTC ACC GCT TCA GAA AAC CAC  
CTC AGA CAC TGC CTC AGC TGC TCC AAA TGC CGA AAG GAA ATG  
GGT CAG GTG GAG ATC TCT TCT TGC ACA GTG GAC CGG GAC ACC  
GTG TGT GGC TGC AGG AAG AAC CAG TAC CGG CAT TAT TGG AGT  
GAA AAC CTT TTC CAG TGC TTC AAT TGC AGC CTC TGC CTC AAT  
GGG ACC GTG CAC CTC TCC TGC CAG GAG AAA CAG AAC ACC GTG  
TGC ACC TGC CAT GCA GGT TTC TTT CTA AGA GAA AAC GAG TGT  
GTC TCC TGT AGT AAC TGT AAG AAA AGC CTG GAG TGC ACG AAG  
TTG TGC CTA CCC CAG ATT GAG AAT GTT AAG GGC ACT GAG GAC  
TCA GGC ACC ACA

, or a C- and/or N- terminally shortened sequence thereof; and

I) DNA comprising the sequence:

ATG GGC CTC TCC ACC GTG CCT GAC CTG CTG CTG CCA CTG GTG  
CTC CTG GAG CTG TTG GTG GGA ATA TAC CCC TCA GGG GTT ATT  
GGA CTG GTC CCT CAC CTA GGG GAC AGG GAG AAG AGA GAT AGT  
GTG TGT CCC CAA GGA AAA TAT ATC CAC CCT CAA AAT AAT TCG  
ATT TGC TGT ACC AAG TGC CAC AAA GGA ACC TAC TTG TAC AAT



*Handwritten: E' cont.*

GAC TGT CCA GGC CCG GGG CAG GAT ACG GAC TGC AGG GAG TGT  
GAG AGC GGC TCC TTC ACC GCT TCA GAA AAC CAC CTC AGA CAC  
TGC CTC AGC TGC TCC AAA TGC CGA AAG GAA ATG GGT CAG GTG  
GAG ATC TCT TCT TGC ACA GTG GAC CGG GAC ACC GTG TGT GGC  
TGC AGG AAG AAC CAG TAC CGG CAT TAT TGG AGT GAA AAC CTT  
TTC CAG TGC TTC AAT TGC AGC CTC TGC CTC AAT GGG ACC GTG  
CAC CTC TCC TGC CAG GAG AAA CAG AAC ACC GTG TGC ACC TGC  
CAT GCA GGT TTC TTT CTA AGA GAA AAC GAG TGT GTC TCC TGT  
AGT AAC TGT AAG AAA AGC CTG GAG TGC ACG AAG TTG TGC CTA  
CCC CAG ATT GAG AAT GTT AAG GGC ACT GAG GAC TCA GGC ACC  
ACA GTG CTG TTG CCC CTG GTC ATT TTC TTT GGT CTT TGC CTT  
TTA TCC CTC CTC TTC ATT GGT TTA ATG TAT CGC TAC CAA CGG  
TGG AAG TCC AAG CTC TAC TCC ATT GTT TGT GGG AAA TCG ACA  
CCT GAA AAA GAG GGG GAG CTT GAA GGA ACT ACT ACT AAG CCC  
CTG GCC CCA AAC CCA AGC TTC AGT CCC ACT CCA GGC TTC ACC  
CCC ACC CTG GGC TTC AGT CCC GTG CCC AGT TCC ACC TTC ACC  
TCC AGC TCC ACC TAT ACC CCC GGT GAC TGT CCC AAC TTT GCG  
GCT CCC CGC AGA GAG GTG GCA CCA CCC TAT CAG GGG GCT GAC  
CCC ATC CTT GCG ACA GCC CTC GCC TCC GAC CCC ATC CCC AAC  
CCC CTT CAG AAG TGG GAG GAC AGC GCC CAC AAG CCA CAG AGC  
CTA GAC ACT GAT GAC CCC GCG ACG CTG TAC GCC GTG GTG GAG  
AAC GTG CCC CCG TTG CGC TGG AAG GAA TTC GTG CGG CGC CTA  
GGG CTG AGC GAC CAC GAG ATC GAT CGG CTG GAG CTG CAG AAC  
GGG CGC TCC CTG CGC GAG GCG CAA TAC AGC ATG CTG GCG ACC  
TGG AGG CGG CGC ACG CCG CGG CGC GAG GCC ACG CTG GAG CTG  
CTG GGA CGC GTG CTC CGC GAC ATG GAC CTG CTG GGC TGC CTG  
GAG GAC ATC GAG GAG GCG CTT TGC GGC CCC GCC GCC CTC CCG  
CCC GCG CCC AGT CTT CTC AGA

, or a C- and/or N- terminally shortened sequence thereof.

81. Polypeptide according to claim 80, wherein said polypeptide is not associated with human urinary proteins.

82. A recombinant polypeptide which is nonglycosylated or has a glycosylation pattern different from urinary-derived TNF inhibitor and has the ability to bind to TNF, characterized in that the polypeptide is encoded by a nucleic acid which hybridizes with DNA complementary to the DNA defined in claim 69 under conditions of moderate stringency.

83. A recombinant polypeptide which is nonglycosylated or has a glycosylation pattern different from urinary-derived TNF inhibitor and has the ability to bind to TNF, wherein said polypeptide is selected from the group consisting of:

A) a polypeptide comprising the amino acid sequence:

R<sup>2</sup> asp ser val cys pro gln gly lys tyr ile his pro gln asn  
 asn ser ile cys cys thr lys cys his lys gly thr tyr leu  
 tyr asn asp cys pro gly pro gly gln asp thr asp cys arg  
 glu cys glu ser gly ser phe thr ala ser glu asn his leu  
 arg his cys leu ser cys ser lys cys arg lys glu met gly  
 gln val glu ile ser ser cys thr val asp arg asp thr val  
 cys gly cys arg lys asn gln tyr arg his tyr trp  
 ser glu asn leu phe gln cys phe asn cys ser leu cys leu  
 asn gly thr val his leu ser cys gln glu lys gln asn thr  
 val cys thr cys his ala gly phe phe leu arg glu asn glu  
 cys val ser cys ser asn cys lys lys ser leu glu cys thr  
 lys leu cys leu pro gln ile glu asn

, or a C- and/or N- terminally shortened sequence thereof, wherein R<sup>2</sup> is absent or is a polypeptide which can be cleaved *in vivo*; and

B) a polypeptide comprising the amino acid sequence:

R<sup>2</sup> asp ser val cys pro gln gly lys tyr ile his pro gln asn  
 asn ser ile cys cys thr lys cys his lys gly thr tyr leu  
 tyr asn asp cys pro gly pro gly gln asp thr asp cys arg  
 glu cys glu ser gly ser phe thr ala ser glu asn his leu  
 arg his cys leu ser cys ser lys cys arg lys glu met gly  
 gln val glu ile ser ser cys thr val asp arg asp thr val  
 cys gly cys arg lys asn gln tyr arg his tyr trp ser glu  
 asn leu phe gln cys phe asn cys ser leu cys leu asn gly  
 thr val his leu ser cys gln glu lys gln asn thr val cys  
 thr cys his ala gly phe phe leu arg glu asn glu cys val  
 ser cys ser asn cys lys lys ser leu glu cys thr lys leu  
 cys leu pro gln ile glu asn val lys gly thr glu asp ser  
 gly thr thr

, or a C- and/or N- terminally shortened sequence thereof, wherein R<sup>2</sup> is absent or is a polypeptide which can be cleaved *in vivo*.

<sup>13</sup> 84. Polypeptide according to claim 83, wherein R<sup>2</sup> is a polypeptide comprising an amino acid sequence which can be cleaved *in vivo*.

<sup>14</sup> 85. Polypeptide according to claim 84, wherein R<sup>2</sup> is a polypeptide comprising the amino acid sequence :

<sup>13</sup>  
T0880 met gly leu ser thr val pro asp leu leu leu pro leu val  
leu leu glu leu leu val gly ile tyr pro ser gly val ile  
gly

; or a C- and/or N- terminally shortened sequence thereof.

86. Polypeptide according to claim 83, wherein said polypeptide is not associated with human urinary proteins.

87. A polypeptide having the ability to bind to TNF comprising an amino acid sequence as set forth in claim 83 with at least one intrasequence conservative amino acid substitution in the sequence of claim 83.

88. Polypeptide according to claim 87, wherein said polypeptide includes at least one additional amino acid at the amino-terminus, at the carboxyl-terminus, or at both the amino-terminus and at the carboxyl-terminus.

89. Polypeptide according to claim 88, wherein said polypeptide includes at least one additional amino acid at the amino-terminus and at the carboxyl-terminus.

90. Polypeptide according to claim 88, wherein said polypeptide includes at least one additional amino acid at the amino-terminus.

91. Polypeptide according to claim 90, wherein said polypeptide includes a methionine at the amino-terminus.

92. Polypeptide according to claim 88, wherein said polypeptide includes at least one additional amino acid at the carboxyl-terminus.

93. Polypeptide according to claim 87, wherein said polypeptide includes a methionine at the amino-terminus and said amino acid substitution is at a glycosylation site.

94. Polypeptide according to claim 87, wherein said amino acid substitution is at a glycosylation site.

95. A recombinant polypeptide which is nonglycosylated or has a glycosylation pattern different from urinary-derived TNF inhibitor and has the ability to bind to TNF, characterized in that the polypeptide is encoded by a nucleic acid which hybridizes with DNA complementary to the DNA defined in claim 83 under conditions of moderate stringency.

96. Polypeptide according to claim 83, wherein said polypeptide is selected from the group consisting of:

A) a polypeptide comprising the amino acid sequence:

asp ser val cys pro gln gly lys tyr ile his pro gln asn  
asn ser ile cys cys thr lys cys his lys gly thr tyr leu  
tyr asn asp cys pro gly pro gly gln asp thr asp cys arg  
glu cys glu ser gly ser phe thr ala ser glu asn his leu  
arg his cys leu ser cys ser lys cys arg lys glu met gly  
gln val glu ile ser ser cys thr val asp arg asp thr val  
cys gly cys arg lys asn gln tyr arg his tyr trp  
ser glu asn leu phe gln cys phe asn cys ser leu cys leu  
asn gly thr val his leu ser cys gln glu lys gln asn thr  
val cys thr cys his ala gly phe phe leu arg glu asn glu  
cys val ser cys ser asn cys lys lys ser leu glu cys thr  
lys leu cys leu pro gln ile glu asn

, or a C- and/or N- terminally shortened sequence thereof;

B) a polypeptide comprising the amino acid sequence:

leu val pro his leu gly asp arg glu lys arg asp ser val  
cys pro gln gly lys tyr ile his pro gln asn asn ser ile  
cys cys thr lys cys his lys gly thr tyr leu tyr asn asp  
cys pro gly pro gly gln asp thr asp cys arg glu cys glu  
ser gly ser phe thr ala ser glu asn his leu arg his cys  
leu ser cys ser lys cys arg lys glu met gly gln val glu  
ile ser ser cys thr val asp arg asp thr val cys gly cys  
arg lys asn gln tyr arg his tyr trp ser glu asn leu phe  
gln cys phe asn cys ser leu cys leu asn gly thr val his  
leu ser cys gln glu lys gln asn thr val cys thr cys his

ala	gly	phe	phe	leu	arg	glu	asn	glu	cys	val	ser	cys	ser
asn	cys	lys	lys	ser	leu	glu	cys	thr	lys	leu	cys	leu	pro
gln	ile	glu	asn										

, or a C- and/or N- terminally shortened sequence thereof;

C) a polypeptide comprising the amino acid sequence:

asp	ser	val	cys	pro	gln	gly	lys	tyr	ile	his	pro	gln	asn
asn	ser	ile	cys	cys	thr	lys	cys	his	lys	gly	thr	tyr	leu
tyr	asn	asp	cys	pro	gly	pro	gly	gln	asp	thr	asp	cys	arg
glu	cys	glu	ser	gly	ser	phe	thr	ala	ser	glu	asn	his	leu
arg	his	cys	leu	ser	cys	ser	lys	cys	arg	lys	glu	met	gly
gln	val	glu	ile	ser	ser	cys	thr	val	asp	arg	asp	thr	val
cys	gly	cys	arg	lys	asn	gln	tyr	arg	his	tyr	trp	ser	glu
asn	leu	phe	gln	cys	phe	asn	cys	ser	leu	cys	leu	asn	gly
thr	val	his	leu	ser	cys	gln	glu	lys	gln	asn	thr	val	cys
thr	cys	his	ala	gly	phe	phe	leu	arg	glu	asn	glu	cys	val
ser	cys	ser	asn	cys	lys	lys	ser	leu	glu	cys	thr	lys	leu
cys	leu	pro	gln	ile	glu	asn	val	lys	gly	thr	glu	asp	ser
gly	thr	thr											

, or a C- and/or N- terminally shortened sequence thereof; and

D) a polypeptide comprising the amino acid sequence:

leu	val	pro	his	leu	gly	asp	arg	glu	lys	arg	asp	ser	val
cys	pro	gln	gly	lys	tyr	ile	his	pro	gln	asn	asn	ser	ile
cys	cys	thr	lys	cys	his	lys	gly	thr	tyr	leu	tyr	asn	asp
cys	pro	gly	pro	gly	gln	asp	thr	asp	cys	arg	glu	cys	glu
ser	gly	ser	phe	thr	ala	ser	glu	asn	his	leu	arg	his	cys
leu	ser	cys	ser	lys	cys	arg	lys	glu	met	gly	gln	val	glu
ile	ser	ser	cys	thr	val	asp	arg	asp	thr	val	cys	gly	cys
arg	lys	asn	gln	tyr	arg	his	tyr	trp	ser	glu	asn	leu	phe
gln	cys	phe	asn	cys	ser	leu	cys	leu	asn	gly	thr	val	his
leu	ser	cys	gln	glu	lys	gln	asn	thr	val	cys	thr	cys	his
ala	gly	phe	phe	leu	arg	glu	asn	glu	cys	val	ser	cys	ser
asn	cys	lys	lys	ser	leu	glu	cys	thr	lys	leu	cys	leu	pro
gln	ile	glu	asn	val	lys	gly	thr	glu	asp	ser	gly	thr	thr

, or a C- and/or N- terminally shortened sequence thereof.

E

97. Polypeptide according to claim 96, wherein said polypeptide includes at least one additional amino acid at the amino-terminus, at the carboxyl-terminus, or at both the amino-terminus and at the carboxyl-terminus.

98. Polypeptide according to claim 97, wherein said polypeptide includes at least one additional amino acid at the amino-terminus and at the carboxyl-terminus.

99. Polypeptide according to claim 97, wherein said polypeptide includes at least one additional amino acid at the amino-terminus.

100. Polypeptide according to claim 99, wherein said polypeptide includes a methionine at the amino-terminus.

101. Polypeptide according to claim 97, wherein said polypeptide includes at least one additional amino acid at the carboxyl-terminus.

102. Polypeptide according to claim 96, wherein said polypeptide is not associated with human urinary proteins.

103. A recombinant polypeptide which is nonglycosylated or has a glycosylation pattern different from urinary-derived TNF inhibitor and has the ability to bind to TNF, wherein said polypeptide is selected from the group consisting of:

A) a polypeptide comprising the amino acid sequence:

met	asp	ser	val	cys	pro	gln	gly	lys	tyr	ile	his	pro	gln
asn	asn	ser	ile	cys	cys	thr	lys	cys	his	lys	gly	thr	tyr
leu	tyr	asn	asp	cys	pro	gly	pro	gly	gln	asp	thr	asp	cys
arg	glu	cys	glu	ser	gly	ser	phe	thr	ala	ser	glu	asn	his
leu	arg	his	cys	leu	ser	cys	ser	lys	cys	arg	lys	glu	met
gly	gln	val	glu	ile	ser	ser	cys	thr	val	asp	arg	asp	thr
val	cys	gly	cys	arg	lys	asn	gln	tyr	arg	his	tyr	trp	ser
glu	asn	leu	phe	gln	cys	phe	asn	cys	ser	leu	cys	leu	asn
gly	thr	val	his	leu	ser	cys	gln	glu	lys	gln	asn	thr	val
cys	thr	cys	his	ala	gly	phe	phe	leu	arg	glu	asn	glu	cys
val	ser	cys	ser	asn	cys	lys	lys	ser	leu	glu	cys	thr	lys
leu	cys	leu	pro	gln	ile	glu	asn						

, or a C- and/or N- terminally shortened sequence thereof;

B) a polypeptide comprising the amino acid sequence:

met	leu	val	pro	his	leu	gly	asp	arg	glu	lys	arg	asp	ser
val	cys	pro	gln	gly	lys	tyr	ile	his	pro	gln	asn	asn	ser
ile	cys	cys	thr	lys	cys	his	lys	gly	thr	tyr	leu	tyr	asn
asp	cys	pro	gly	pro	gly	gln	asp	thr	asp	cys	arg	glu	cys
glu	ser	gly	ser	phe	thr	ala	ser	glu	asn	his	leu	arg	his
cys	leu	ser	cys	ser	lys	cys	arg	lys	glu	met	gly	gln	val
glu	ile	ser	ser	cys	thr	val	asp	arg	asp	thr	val	cys	gly
cys	arg	lys	asn	gln	tyr	arg	his	tyr	trp	ser	glu	asn	leu
phe	gln	cys	phe	asn	cys	ser	leu	cys	leu	asn	gly	thr	val
his	leu	ser	cys	gln	glu	lys	gln	asn	thr	val	cys	thr	cys
his	ala	gly	phe	phe	leu	arg	glu	asn	glu	cys	val	ser	cys
ser	asn	cys	lys	lys	ser	leu	glu	cys	thr	lys	leu	cys	leu
pro	gln	ile	glu	asn									

, or a C- and/or N- terminally shortened sequence thereof;

C) a polypeptide comprising the amino acid sequence:

met	asp	ser	val	cys	pro	gln	gly	lys	tyr	ile	his	pro	gln
asn	asn	ser	ile	cys	cys	thr	lys	cys	his	lys	gly	thr	tyr
leu	tyr	asn	asp	cys	pro	gly	pro	gly	gln	asp	thr	asp	cys
arg	glu	cys	glu	ser	gly	ser	phe	thr	ala	ser	glu	asn	his
leu	arg	his	cys	leu	ser	cys	ser	lys	cys	arg	lys	glu	met
gly	gln	val	glu	ile	ser	ser	cys	thr	val	asp	arg	asp	thr
val	cys	gly	cys	arg	lys	asn	gln	tyr	arg	his	tyr	trp	ser
glu	asn	leu	phe	gln	cys	phe	asn	cys	ser	leu	cys	leu	asn
gly	thr	val	his	leu	ser	cys	gln	glu	lys	gln	asn	thr	val
cys	thr	cys	his	ala	gly	phe	phe	leu	arg	glu	asn	glu	cys
val	ser	cys	ser	asn	cys	lys	lys	ser	leu	glu	cys	thr	lys
leu	cys	leu	pro	gln	ile	glu	asn	val	lys	gly	thr	glu	asp
ser	gly	thr	thr										

, or a C- and/or N- terminally shortened sequence thereof;

D) a polypeptide comprising the amino acid sequence:

met	leu	val	pro	his	leu	gly	asp	arg	glu	lys	arg	asp	ser
val	cys	pro	gln	gly	lys	tyr	ile	his	pro	gln	asn	asn	ser
ile	cys	cys	thr	lys	cys	his	lys	gly	thr	tyr	leu	tyr	asn

5' cont.  
Back to Cont 7

3

asp	cys	pro	gly	pro	gly	gln	asp	thr	asp	cys	arg	glu	cys
glu	ser	gly	ser	phe	thr	ala	ser	glu	asn	his	leu	arg	his
cys	leu	ser	cys	ser	lys	cys	arg	lys	glu	met	gly	gln	val
glu	ile	ser	ser	cys	thr	val	asp	arg	asp	thr	val	cys	gly
cys	arg	lys	asn	gln	tyr	arg	his	tyr	trp	ser	glu	asn	leu
phe	gln	cys	phe	asn	cys	ser	leu	cys	leu	asn	gly	thr	val
his	leu	ser	cys	gln	glu	lys	gln	asn	thr	val	cys	thr	cys
his	ala	gly	phe	phe	leu	arg	glu	asn	glu	cys	val	ser	cys
ser	asn	cys	lys	lys	ser	leu	glu	cys	thr	lys	leu	cys	leu
pro	gln	ile	glu	asn	val	lys	gly	thr	glu	asp	ser	gly	thr

, or a C- and/or N- terminally shortened sequence thereof;

E) a polypeptide comprising the amino acid sequence:

met	gly	leu	ser	thr	val	pro	asp	leu	leu	leu	pro	leu	val
leu	leu	glu	leu	leu	val	gly	ile	tyr	pro	ser	gly	val	ile
gly	leu	val	pro	his	leu	gly	asp	arg	glu	lys	arg	asp	ser
val	cys	pro	gln	gly	lys	tyr	ile	his	pro	gln	asn	asn	ser
ile	cys	cys	thr	lys	cys	his	lys	gly	thr	tyr	leu	tyr	asn
asp	cys	pro	gly	pro	gly	gln	asp	thr	asp	cys	arg	glu	cys
glu	ser	gly	ser	phe	thr	ala	ser	glu	asn	his	leu	arg	his
cys	leu	ser	cys	ser	lys	cys	arg	lys	glu	met	gly	gln	val
glu	ile	ser	ser	cys	thr	val	asp	arg	asp	thr	val	cys	gly
cys	arg	lys	asn	gln	tyr	arg	his	tyr	trp	ser	glu	asn	leu
phe	gln	cys	phe	asn	cys	ser	leu	cys	leu	asn	gly	thr	val
his	leu	ser	cys	gln	glu	lys	gln	asn	thr	val	cys	thr	cys
his	ala	gly	phe	phe	leu	arg	glu	asn	glu	cys	val	ser	cys
ser	asn	cys	lys	lys	ser	leu	glu	cys	thr	lys	leu	cys	leu
pro	gln	ile	glu	asn									

, or a C- and/or N- terminally shortened sequence thereof;

F) a polypeptide comprising the amino acid sequence:

met	gly	leu	ser	thr	val	pro	asp	leu	leu	leu	pro	leu	val
leu	leu	glu	leu	leu	val	gly	ile	tyr	pro	ser	gly	val	ile
gly	leu	val	pro	his	leu	gly	asp	arg	glu	lys	arg	asp	ser
val	cys	pro	gln	gly	lys	tyr	ile	his	pro	gln	asn	asn	ser
ile	cys	cys	thr	lys	cys	his	lys	gly	thr	tyr	leu	tyr	asn

E



asp	cys	pro	gly	pro	gly	gln	asp	thr	asp	cys	arg	glu	cys
glu	ser	gly	ser	phe	thr	ala	ser	glu	asn	his	leu	arg	his
cys	leu	ser	cys	ser	lys	cys	arg	lys	glu	met	gly	gln	val
glu	ile	ser	ser	cys	thr	val	asp	arg	asp	thr	val	cys	gly
cys	arg	lys	asn	gln	tyr	arg	his	tyr	trp	ser	glu	asn	leu
phe	gln	cys	phe	asn	cys	ser	leu	cys	leu	asn	gly	thr	val
his	leu	ser	cys	gln	glu	lys	gln	asn	thr	val	cys	thr	cys
his	ala	gly	phe	phe	leu	arg	glu	asn	glu	cys	val	ser	cys
ser	asn	cys	lys	lys	ser	leu	glu	cys	thr	lys	leu	cys	leu
pro	gln	ile	glu	asn	val	lys	gly	thr	glu	asp	ser	gly	thr

, or a C- and/or N- terminally shortened sequence thereof;

G) a polypeptide comprising the amino acid sequence:

met	gly	leu	ser	thr	val	pro	asp	leu	leu	leu	pro	leu	val
leu	leu	glu	leu	leu	val	gly	ile	tyr	pro	ser	gly	val	ile
gly	asp	ser	val	cys	pro	gln	gly	lys	tyr	ile	his	pro	gln
asn	asn	ser	ile	cys	cys	thr	lys	cys	his	lys	gly	thr	tyr
leu	tyr	asn	asp	cys	pro	gly	pro	gly	gln	asp	thr	asp	cys
arg	glu	cys	glu	ser	gly	ser	phe	thr	ala	ser	glu	asn	his
leu	arg	his	cys	leu	ser	cys	ser	lys	cys	arg	lys	glu	met
gly	gln	val	glu	ile	ser	ser	cys	thr	val	asp	arg	asp	thr
val	cys	gly	cys	arg	lys	asn	gln	tyr	arg	his	tyr	trp	ser
glu	asn	leu	phe	gln	cys	phe	asn	cys	ser	leu	cys	leu	asn
gly	thr	val	his	leu	ser	cys	gln	glu	lys	gln	asn	thr	val
cys	thr	cys	his	ala	gly	phe	phe	leu	arg	glu	asn	glu	cys
val	ser	cys	ser	asn	cys	lys	lys	ser	leu	glu	cys	thr	lys
leu	cys	leu	pro	gln	ile	glu	asn						

, or a C- and/or N- terminally shortened sequence thereof;

H) a polypeptide comprising the amino acid sequence:

met	gly	leu	ser	thr	val	pro	asp	leu	leu	leu	pro	leu	val
leu	leu	glu	leu	leu	val	gly	ile	tyr	pro	ser	gly	val	ile
gly	asp	ser	val	cys	pro	gln	gly	lys	tyr	ile	his	pro	gln
asn	asn	ser	ile	cys	cys	thr	lys	cys	his	lys	gly	thr	tyr
leu	tyr	asn	asp	cys	pro	gly	pro	gly	gln	asp	thr	asp	cys
arg	glu	cys	glu	ser	gly	ser	phe	thr	ala	ser	glu	asn	his

*E*

leu	arg	his	cys	leu	ser	cys	ser	lys	cys	arg	lys	glu	met
gly	gln	val	glu	ile	ser	ser	cys	thr	val	asp	arg	asp	thr
val	cys	gly	cys	arg	lys	asn	gln	tyr	arg	his	tyr	trp	ser
glu	asn	leu	phe	gln	cys	phe	asn	cys	ser	leu	cys	leu	asn
gly	thr	val	his	leu	ser	cys	gln	glu	lys	gln	asn	thr	val
cys	thr	cys	his	ala	gly	phe	phe	leu	arg	glu	asn	glu	cys
val	ser	cys	ser	asn	cys	lys	lys	ser	leu	glu	cys	thr	lys
leu	cys	leu	pro	gln	ile	glu	asn	val	lys	gly	thr	glu	asp
ser	gly	thr	thr										

, or a C- and/or N- terminally shortened sequence thereof; and

l) a polypeptide comprising the amino acid sequence:

met	gly	leu	ser	thr	val	pro	asp	leu	leu	leu	pro	leu	val
leu	leu	glu	leu	leu	val	gly	ile	tyr	pro	ser	gly	val	ile
gly	leu	val	pro	his	leu	gly	asp	arg	glu	lys	arg	asp	ser
val	cys	pro	gln	gly	lys	tyr	ile	his	pro	gln	asn	asn	ser
ile	cys	cys	thr	lys	cys	his	lys	gly	thr	tyr	leu	tyr	asn
asp	cys	pro	gly	pro	gly	gln	asp	thr	asp	cys	arg	glu	cys
glu	ser	gly	ser	phe	thr	ala	ser	glu	asn	his	leu	arg	his
cys	leu	ser	cys	ser	lys	cys	arg	lys	glu	met	gly	gln	val
glu	ile	ser	ser	cys	thr	val	asp	arg	asp	thr	val	cys	gly
cys	arg	lys	asn	gln	tyr	arg	his	tyr	trp	ser	glu	asn	leu
phe	gln	cys	phe	asn	cys	ser	leu	cys	leu	asn	gly	thr	val
his	leu	ser	cys	gln	glu	lys	gln	asn	thr	val	cys	thr	cys
his	ala	gly	phe	phe	leu	arg	glu	asn	glu	cys	val	ser	cys
ser	asn	cys	lys	lys	ser	leu	glu	cys	thr	lys	leu	cys	leu
pro	gln	ile	glu	asn	val	lys	gly	thr	glu	asp	ser	gly	thr
thr	val	leu	leu	pro	leu	val	ile	phe	phe	gly	leu	cys	leu
leu	ser	leu	leu	phe	ile	gly	leu	met	tyr	arg	tyr	gln	arg
trp	lys	ser	lys	leu	tyr	ser	ile	val	cys	gly	lys	ser	thr
pro	glu	lys	glu	gly	glu	leu	glu	gly	thr	thr	thr	lys	pro
leu	ala	pro	asn	pro	ser	phe	ser	pro	thr	pro	gly	phe	thr
pro	thr	leu	gly	phe	ser	pro	val	pro	ser	ser	thr	phe	thr
ser	ser	ser	thr	tyr	thr	pro	gly	asp	cys	pro	asn	phe	ala
ala	pro	arg	arg	glu	val	ala	pro	pro	tyr	gln	gly	ala	asp
pro	ile	leu	ala	thr	ala	leu	ala	ser	asp	pro	ile	pro	asn
pro	leu	gln	lys	trp	glu	asp	ala	thr	his	lys	pro	gln	ser
leu	asp	thr	asp	asp	pro	ala	thr	leu	tyr	ala	val	val	glu
asn	val	pro	pro	leu	arg	trp	lys	glu	phe	val	arg	arg	leu

*Sub P1  
Cont*

gly	leu	ser	asp	his	glu	ile	asp	arg	leu	glu	leu	gln	asn
gly	arg	cys	leu	arg	glu	ala	gln	tyr	ser	met	leu	ala	thr
trp	arg	arg	arg	thr	pro	arg	arg	glu	ala	thr	leu	glu	leu
leu	gly	arg	val	leu	arg	asp	met	asp	leu	leu	gly	cys	leu
glu	asp	ile	glu	glu	ala	leu	cys	gly	pro	ala	ala	leu	pro
pro	ala	pro	ser	leu	leu	arg							

, or a C- and/or N- terminally shortened sequence thereof.

*E' word.*

104. Polypeptide according to claim 103, wherein said polypeptide includes at least one additional amino acid at the amino-terminus, at the carboxyl-terminus, or at both the amino-terminus and at the carboxyl-terminus.

105. Polypeptide according to claim 104, wherein said polypeptide includes at least one additional amino acid at the carboxyl-terminus.

106. Polypeptide according to claim 103, wherein said polypeptide is not associated with human urinary proteins.--

### **REMARKS**

Claims 40 to 48 and 54 to 66 have been canceled without prejudice or disclaimer.

Claims 27, 49, 67, and 68 have been amended to change their dependency. Claims 69 to 106 have been added. Thus, claims 24, 27 to 39, 49 to 53, 67, 68, and 69 to 106 are pending. The amendments and the cancellation of claims have not been made in response to a rejection or in acquiescence to a rejection. The amendments have been made to even more clearly recite the applicants' inventions.

Solely to expedite prosecution, applicants have amended and canceled claims such that the term "variant" is not included in the claims. The terms "variant" (other than "degenerate variants") was not included in the claims as previously examined, and thus, there

*E*